InvestorsHub Logo
icon url

tikotiko

05/12/21 12:41 PM

#164857 RE: DonDonDonDon #164847

...and you base your statement on your statistical expertise of course.
Please....
icon url

wsbull

05/12/21 12:42 PM

#164858 RE: DonDonDonDon #164847

I think 82% in 14 days is probably true, that would be a pretty egregious lie.

If it is true, the problem is instead of partnering with BP and NIH/BARDA like other small caps (VIR, HGEN) to figure out what patient population and dosing LL would work with, NP threw darts at the wall and hoped one would stick.

The question is whether this naively was done to save time, money and partnership costs, or whether BP and the gov't didn't want to cooperate with CytoDyn because of their track record.
icon url

3X Charm

05/12/21 1:01 PM

#164872 RE: DonDonDonDon #164847

Ok. Didn’t realize that. Perhaps the older more severe cases were enrolled later in the trial. In any event
A new CRO is needed to design the trials and perhaps that is the case in Brazil.